Vistagen Therapeutics Sued for Securities Law Violations: DJS Law Group Investigating Class Action Lawsuit.

Vistagen Therapeutics is being sued for securities law violations by the DJS Law Group. Shareholders who purchased shares during the class period (April 1, 2024 to December 16, 2025) are encouraged to contact the firm regarding possible lead plaintiff appointments. The lawsuit alleges that the company made false and misleading statements about the results of its PALISADE-2 trial of fasedienol, creating a false impression that the drug candidate would enjoy a successful Phase 3 trial. The deadline to participate is March 16, 2026.